Device Trial Radar · NCT07889388
RIGHTEST iFree 2 CGM in Pregnant Women With Diabetes Study
Last checked: Nov 19, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
104
Planned (sponsor's estimate)
Start
Jun 9, 2026
Primary completion
Mar 2027
Study completion Mar 2027
Sponsor
- Lead sponsor
- Bionime CorporationNot on our public-company list
- Sponsor type
- Industry
- First posted
- Oct 22, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Other
- FDA-regulated device
- No
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate the accuracy and safety of the RIGHTEST iFree 2 Continuous Glucose Monitoring (CGM) System in pregnant women with type 1 diabetes, type 2 diabetes, or gestational diabetes. The system uses a small sensor placed under the skin to measure glucose levels in the fluid between cells. Approximately 104 women will participate at study sites in Germany and Taiwan. Each participant will wear two sensors, one on each upper arm, for up to 15 days. During one clinic visit lasting up to six hours, blood samples will be collected every 15 minutes. Sensor readings will be compared with laboratory blood glucose measurements to assess accuracy. Participants will also be assessed for side effects, including skin reactions at the sensor sites, and will receive a safety follow-up after sensor removal. No procedures will be used to deliberately raise or lower blood glucose levels.
Conditions
- Diabetes Mellitus, Type 1 Diabetes
- Diabetes Mellitus, Type 2
- Diabetes, Gestational
Interventions
RIGHTEST iFree 2 Continuous Glucose Monitoring SystemDevice
The RIGHTEST iFree 2 Continuous Glucose Monitoring System (Bionime Corporation) measures interstitial glucose continuously for up to 15 days.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of CGM Readings Within ±20% of Reference Blood Glucose MeasurementsTime frame: During one sampling session of up to 6 hours on Day 1, Day 5 ±1, Day 10 ±1, or Day 15 of sensor wear.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Institut für Diabetes-Technologie Forschungs- und Entwicklungsgesellschaft mbH an der Universität Ulm
Ulm, Baden-Wurttemberg, Germany · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.